Multiple autoimmune complications after a single dose of Pembrolizumab

Authors

Hardeep S. Ahdi, Advocate Aurora HealthFollow
Sufyan Abdulmujeeb, Advocate Aurora HealthFollow
Edward Nabrinsky, Advocate Aurora HealthFollow

Recommended Citation

Ahdi HS, Abdulmujeeb S, Nabrinsky E. Multiple Autoimmune Complications After a Single Dose of Pembrolizumab. Cureus. 2023;15(3):e35871. Published 2023 Mar 7. doi:10.7759/cureus.35871

Affiliations

Advocate Lutheran General Hospital, Advocate Sherman Hospital

Abstract

Pembrolizumab, a monoclonal antibody that inhibits programmed cell death protein-1 (PD-1), is an important treatment for various malignancies. Unfortunately, it has also been associated with a wide array of immune-related adverse events. We present a unique case of a patient who received a single dose of pembrolizumab and subsequently developed multiple immune-mediated complications, including dermatitis, hepatitis, myositis, myocarditis, and myasthenia gravis.

Type

Article

PubMed ID

37033516